Edta collection tubes

Manufactured by Sarstedt

Sourced in Germany

EDTA collection tubes are laboratory equipment used for the collection and storage of blood samples. They contain the anticoagulant Ethylenediaminetetraacetic acid (EDTA), which prevents the blood from clotting during the collection and transportation process.

Automatically generated - may contain errors

Lab products found in correlation

Serum gel, by Sarstedt (1 mentions) P800 tubes, by BD (1 mentions) Daytona, by Randox (1 mentions) Cellsave tubes, by Johnson & Johnson (1 mentions) Resiquimod, by Merck Group (1 mentions)

Close spelling variants of this product

Microvette 100 potassium-EDTA blood collection tubes Potassium EDTA collection tubes S-Monovette K3 EDTA blood collection tubes K3 EDTA S-Monovette collection tubes EDTA-buffered collection tubes EDTA-coated blood collection tubes K2-EDTA collection tubes Collection tubes EDTA tubes

6 protocols using edta collection tubes

Cytogenetic Evaluation of AML Patients

Check if the same lab product or an alternative is used in the 5 most similar protocols

The study group consisted of 50 consecutive patients (19 women and 31 men) aged between 18 and 74 years, hospitalized at the Department of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin in the years 2008–2012. The preliminary diagnosis of AML was based on standard FAB (French-American-British) criteria. The follow-up covered a period of 3 years (36 months).
With informed consent (approval number of the University Ethics Committee: KE-254/24/2011) the bone marrow aspirates were collected to heparin and EDTA collection tubes (Sarstedt, Germany), to be used for cell culture and for DNA isolation, respectively. Twenty-four and 72-hour unstimulated cell cultures were terminated conventionally, then GTG and RHG banded chromosomes were analyzed. Cytogenetic evaluation in selected cases was complemented by the fluorescent in situ hybridization (FISH) technique.
FISH was performed according to the manufacturer's protocol with the probes fort(15;17)(PML/RARα), EVI1, MYC, MLL, TP53 and a probe specific for centromeric sequences of chromosome 8 (all from Vysis, Abbott Laboratories, USA).

Koczkodaj D., Zmorzyński S., Michalak-Wojnowska M., Wąsik-Szczepanek E, & Filip A.A. (2016). Examination of the FLT3 and NPM1 mutational status in patients with acute myeloid leukemia from southeastern Poland. Archives of Medical Science : AMS, 12(1), 120-128.

+ Open protocol

+ Expand

Cytokine Profiling of CFTR Nanotherapies

Check if the same lab product or an alternative is used in the 5 most similar protocols

Ethical approval for using whole blood from healthy donor was obtained from Ethics Commission University Clinic of Tuebingen, Germany (349/2013BO2) and experiments were conducted in accordance with relevant guidelines and regulations. Informed consent form (following WHO guideline) was signed by each volunteer (healthy donor) and kept safely by principal investigator for privacy requirement. Blood samples from three healthy donors were collected in EDTA collection tubes (www.sarstedt.com). For each treatment group, 2 ml of EDTA-blood was transferred into 12-well plates and treated accordingly. R848 (Resiquimod, www.sigmaaldrich.com) was added at a concentration of 1 mg/ml to the respective blood positive controls. cmRNA^hCFTR and pDNA^hCFTR (7 picomol each) were complexed to NPs at a ratio of 1:10. The samples were kept at 37 °C incubator maintaining 5% CO₂. At 6 h and 24 h, 1 ml of whole blood was transferred into microtubes containing serum gel (www.sarstedt.com) and spun down at 10,000 × g for 5 min to obtain serum. Sera were stored at −20 °C for further cytokine measurement analyses. Serum was used to conduct IFN-α, TNF-α and IL-8 ELISA at manufacturer’s instruction (www.thermofisher.com).

Haque A.K., Dewerth A., Antony J.S., Riethmüller J., Schweizer G.R., Weinmann P., Latifi N., Yasar H., Pedemonte N., Sondo E., Weidensee B., Ralhan A., Laval J., Schlegel P., Seitz C., Loretz B., Lehr C.M., Handgretinger R, & Kormann M.S. (2018). Chemically modified hCFTR mRNAs recuperate lung function in a mouse model of cystic fibrosis. Scientific Reports, 8, 16776.

+ Open protocol

+ Expand

Plasma and Serum Sampling for Biomarker Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

A 10-mL blood sample was collected for sampling of arterialised venous blood at each timepoint. This was dispensed into 1) 5-mL EDTA collection tubes (Sarstedt, Nümbrecht, Germany); 2) 3-mL untreated blood collection tubes (Sarstedt, Nümbrecht, Germany); and 3) 2-mL p800 tubes (BD, New Jersey, USA) containing a cocktail of enzyme inhibitors. Plasma samples (EDTA and p800 tubes) underwent immediate centrifugation, whereas untreated blood collection tubes were allowed to clot at room temperature for 15 minutes before being centrifuged to extract blood serum. All samples were centrifuged at 4000 g for (20) . All samples for comparison between treatments within each participant were included on the same plate and the respective intra-plate CVs for GLP-1TOTAL, GLP-17-36amide and Insulin were 6.1%, 6.1%, and 7.4%, respectively.
Plasma glucose and NEFA and serum calcium and albumin were analysed in singular using a spectrophotometric analyser (Randox, Daytona, Randox Laboratories Ltd., Crumlin, UK).

Watkins J.D., Smith H.A., Hengist A., Brunsgaard L.H., Mikkelsen U.R., Koumanov F., Betts J.A, & Gonzalez J.T. (2021). Plasma glucagon-like peptide-1 responses to ingestion of protein with increasing doses of milk minerals rich in calcium. The British journal of nutrition.

+ Open protocol

+ Expand

Blood Sampling for Breast Cancer CTC Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

Blood from healthy individuals and metastatic breast cancer patients was obtained from the Department of Transfusion Medicine and Department of Gynecology at the University Medical Center Hamburg-Eppendorf, respectively. All study participants gave written informed consent. The examination of blood from breast cancer patients was approved by the local ethics review board Aerztekammer Hamburg (OB/V/03). Breast cancer patients’ blood was sampled in EDTA collection tubes (01.1605.001, Sarstedt). Blood from healthy donors was collected either in EDTA or CellSave tubes (7900005, Janssen Diagnostics) and spiked with SK-BR-3 cells to simulate CTCs.

Babayan A., Alawi M., Gormley M., Müller V., Wikman H., McMullin R.P., Smirnov D.A., Li W., Geffken M., Pantel K, & Joosse S.A. (2016). Comparative study of whole genome amplification and next generation sequencing performance of single cancer cells. Oncotarget, 8(34), 56066-56080.

+ Open protocol

+ Expand

mRNA Transfection of Whole Blood

Check if the same lab product or an alternative is used in the 5 most similar protocols

Blood samples from three different healthy donors was taken and collected in EDTA collection tubes (Sarstedt, Germany). For each treatment group, 2 mL EDTA-blood was transferred into 12-well plates and treated accordingly. 10 μL 1 mg/mL (un-)modified mRNAs were complexed to 10 μL TransIT (Mirus Bio, Madison, WI). For a positive control group, blood was treated with the TLR 7 and 8 agonist R-848 (Resiquimod, Sigma-Aldrich, St. Louis, MO). Samples were incubated for 6 or 24 hr at 37°C in a humidified atmosphere containing 5% CO₂. At each time point, 1 mL whole blood was transferred into columns for serum separation (Sarstedt, 41.1378.005) and spun down at 10,000 × g for 5 min to obtain serum. Sera were stored at −20°C until further cytokine measurement analyses.

Vaidyanathan S., Azizian K.T., Haque A.K., Henderson J.M., Hendel A., Shore S., Antony J.S., Hogrefe R.I., Kormann M.S., Porteus M.H, & McCaffrey A.P. (2018). Uridine Depletion and Chemical Modification Increase Cas9 mRNA Activity and Reduce Immunogenicity without HPLC Purification. Molecular Therapy. Nucleic Acids, 12, 530-542.

+ Open protocol

+ Expand

PCSK9 Antibody Effects on Plasma Lipids

Check if the same lab product or an alternative is used in the 5 most similar protocols

Male C57BL/6 mice (Taconic), 10-12 weeks of age at purchase, were randomly assigned to study groups. Groups included a range of 4 to 8 mice. Prior to dosing, animals were mechanically restrained, and 25 μL of blood was collected via tail snip into EDTA collection tubes (Sarstedt AG) and stored on ice. Blood samples were centrifuged at 16,260 g, 4°C for 10 minutes, with resulting plasma aliquoted and frozen at -80°C for subsequent measurement of plasma total cholesterol concentrations. Vehicle (propylene glycol, 20%; 20% Solutol in water, 25%; PBS, 55%) or compound in vehicle (3 mg/mL or 30 mg/kg) was administered twice-daily, 12 hours apart, for 3 days to mice via subcutaneous injection. Mice in the PCSK9 antibody (human IgG1-LALA31H4; Amgen PCSK9 antibody, WO 2009/026558) group received a single intravenous injection of 1 mg/mL (10 mg/kg). Blood samples for the measurement of plasma drug levels were collected immediately prior to dosing throughout the study (every 12 hours) and were processed, as described above. On Day 4, mice were euthanized via CO 2 asphyxiation, blood collected by cardiac puncture and liver samples obtained. A 25-35 mg piece of liver for the measurement of LDLR protein concentration was placed in a 2 mL Eppendorf tube before being frozen on dry ice and stored at -80°C.

Brousseau M.E., Clairmont K.B., Spraggon G., Flyer A.N., Golosov A.A., Grosche P., Amin J., Andre J., Burdick D., Caplan S., Chen G., Chopra R., Ames L., Dubiel D., Fan L., Gattlen R., Kelly-Sullivan D., Koch A.W., Lewis I., Li J., Liu E., Lubicka D., Marzinzik A., Nakajima K., Nettleton D., Ottl J., Pan M., Patel T., Perry L., Pickett S., Poirier J., Reid P.C., Pelle X., Seepersaud M., Subramanian V., Vera V., Xu M., Yang L., Yang Q., Yu J., Zhu G, & Monovich L.G. (2022). Identification of a PCSK9-LDLR disruptor peptide with in vivo function. Cell chemical biology, 29(2).

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!